GlaxoSmithKline's effort to relaunch cancer R&D faces skepticism

GlaxoSmithKline ($GSK) made a high-profile decision to exit the cancer drug field in its recent deal with Novartis ($NVS), but as Reuters reports, a band of specialists inside GSK still has ambitious plans for developing next-gen therapies. GSK is concentrating its hopes on bispecific antibodies and immuno-oncology, which has emerged as the hottest field in drug R&D. Still, the pharma giant is likely to run into considerable skepticism. "It's hard to envision GSK spending a lot of money in an area in which they no longer have a commercial presence," Marshall Gordon, healthcare analyst for ClearBridge Investments, tells Reuters. Story

Suggested Articles

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.